Sugi Predict

Sugi Predict / Compounds / SCHEMBL322170

SCHEMBL322170

SCHEMBL322170

COc1ncc(Br)c(OC)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.53
▸ QPCT Q16769 1/20 0.39
▸ QPCTL Q9NXS2 1/20 0.39
▸ ULK1 O75385 1/20 0.38
▸ CYP1A2 P05177 4/20 0.36
▸ CRHR1 P34998 1/20 0.35
▸ METAP2 P50579 1/20 0.35
▸ PLAU P00749 1/20 0.35
▸ EGFR P00533 2/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ HCK P08631 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ PIK3CB P42338 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ EPHB4 P54760 1/20 0.34
▸ PRKDC P78527 1/20 0.34
▸ PI4KB Q9UBF8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693602 1.00 GAA (0.53) GAAQPCTQPCTLULK1CYP1A2
SCHEMBL1697636 0.84 GAA (0.47) GAAULK1CYP1A2CRHR1TSHR
SCHEMBL17826394 0.82 GAA (0.49) GAAULK1CYP1A2
SCHEMBL9195006 0.80 GAA (0.44) GAAQPCTQPCTLCYP1A2PLAU
SCHEMBL21995602 0.79 ALDH1A1 (0.43) GAAULK1CYP1A2TSHRMEN1
SCHEMBL31366250 0.78 GAA (0.40) GAAULK1TSHRALDH1A1KMT2A
SCHEMBL13004012 0.78 GAA (0.40) GAAULK1TSHRALDH1A1KMT2A
SCHEMBL29421576 0.78 CYP1A2 (0.45) GAACYP1A2EGFRPIK3CATSHR
SCHEMBL21224374 0.78 CYP1A2 (0.45) GAACYP1A2EGFRPIK3CATSHR
SCHEMBL16815393 0.78 GAA (0.41) GAAQPCTQPCTLCYP1A2CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420548-A Preparation method of 2, 4-dimethoxy-5-bromopyrimidine 辽宁工程技术大学 2024-08-02 — — CN claimed
US-20250059181-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2025-02-20 — — US disclosed
US-20240417405-A1 Substituted Spiro Derivatives JANSSEN PHARMACEUTICA NV (BE) 2024-12-19 — — US disclosed
CN-118420548-A Preparation method of 2, 4-dimethoxy-5-bromopyrimidine 辽宁工程技术大学 2024-08-02 — — CN disclosed
CN-118420548-A Preparation method of 2, 4-dimethoxy-5-bromopyrimidine 辽宁工程技术大学 2024-08-02 — — CN disclosed
CN-118420548-A Preparation method of 2, 4-dimethoxy-5-bromopyrimidine 辽宁工程技术大学 2024-08-02 — — CN disclosed
US-12018001-B2 Pyrimidine cyclohexenyl glucocorticoid receptor modulators CORCEPT THERAPEUTICS INCORPORATED (US) 2024-06-25 — — US disclosed
EP-3802499-B1 PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS INC (US) 2024-04-10 — — EP disclosed
US-11935803-B2 Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-03-19 — — US disclosed
CN-117730081-A Substituted spirocyclic derivatives 詹森药业有限公司 2024-03-19 — — CN disclosed
WO-1997012879-A1 HETEROCYCLICALLY SUBSTITUTED SALICYLIC ACID DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1997-04-10 — — WO disclosed
US-5521163-A TREATMENT OF HERPES VIRUS WITH 1'-DEOXY-5-ETHYL-4'-THIO-BETA URIDINE UNIVERSITY OF BIRMINGHAM (GB) 1996-05-28 — — US disclosed
EP-0421777-B1 Further antiviral pyrimidine nucleosides UNIV BIRMINGHAM (GB) 1996-02-28 — — EP disclosed
EP-0658166-A1 ANTIVIRAL PYRIMIDINE NUCLEOSIDES THE UNIVERSITY OF BIRMINGHAM (GB) 1995-06-21 — — EP disclosed
US-5356882-A Treating herpes virus UNIVERSITY OF BIRMINGHAM (GB) 1994-10-18 — — US disclosed
WO-1994005687-A1 ANTIVIRAL PYRIMIDINE NUCLEOSIDES UNIVERSITY OF BIRMINGHAM (GB) 1994-03-17 — — WO disclosed
WO-1991004982-A1 FURTHER ANTIVIRAL PYRIMIDINE NUCLEOSIDES UNIVERSITY OF BIRMINGHAM (GB) 1991-04-18 — — WO disclosed
EP-0421777-A1 Further antiviral pyrimidine nucleosides THE UNIVERSITY OF BIRMINGHAM (GB) 1991-04-10 — — EP disclosed
WO-1991001326-A1 ANTIVIRAL PYRIMIDINE NUCLEOSIDES UNIVERSITY OF BIRMINGHAM (GB) 1991-02-07 — — WO disclosed
EP-0409575-A1 Antiviral pyrimidine nucleosides THE UNIVERSITY OF BIRMINGHAM (GB) 1991-01-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059181-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS GAA 410/4885QPCT 880/4885QPCTL 3213/4885
US-20240417405-A1 Substituted Spiro Derivatives BMI1, MLLT1, MLLT3 GAA 4453/4885QPCT 3759/4885QPCTL 2531/4885
US-12018001-B2 Pyrimidine cyclohexenyl glucocorticoid receptor modulators NR3C1, NR3C2, MC2R GAA 4710/4885QPCT 1305/4885QPCTL 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.